KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Acquisitions & Divestments: 2011-2025

Historic Change in Acquisitions & Divestments for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $468.6 million.

  • Supernus Pharmaceuticals' Change in Acquisitions & Divestments rose 216.34% to $468.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $868.1 million, marking a year-over-year increase of 116.23%. This contributed to the annual value of $498.9 million for FY2024, which is 34.50% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Change in Acquisitions & Divestments stood at $468.6 million for Q3 2025, which was up 324.40% from $110.4 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $468.6 million during Q3 2025, and its lowest value of $17.6 million during Q4 2022.
  • For the 3-year period, Supernus Pharmaceuticals' Change in Acquisitions & Divestments averaged around $145.9 million, with its median value being $133.0 million (2024).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Change in Acquisitions & Divestments crashed by 95.36% in 2022, and later spiked by 729.88% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $378.0 million in 2021, then tumbled by 95.36% to $17.6 million in 2022, then skyrocketed by 102.87% to $35.6 million in 2023, then soared by 273.50% to $133.0 million in 2024, then skyrocketed by 216.34% to $468.6 million in 2025.
  • Its last three reported values are $468.6 million in Q3 2025, $110.4 million for Q2 2025, and $156.2 million during Q1 2025.